These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36789885)

  • 1. Comparative effectiveness of natalizumab on cognition in multiple sclerosis: A cohort study.
    Manouchehrinia A; Larsson H; Karim ME; Lycke J; Olsson T; Kockum I
    Mult Scler; 2023 Apr; 29(4-5):628-636. PubMed ID: 36789885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.
    Perumal J; Balabanov R; Su R; Chang R; Balcer LJ; Galetta SL; Avila RL; Rutledge D; Fox RJ
    CNS Drugs; 2022 Sep; 36(9):977-993. PubMed ID: 36064841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.
    Landmeyer NC; Bürkner PC; Wiendl H; Ruck T; Hartung HP; Holling H; Meuth SG; Johnen A
    Neurology; 2020 Jun; 94(22):e2373-e2383. PubMed ID: 32430312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
    Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T
    Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
    JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.
    Capra R; Morra VB; Mirabella M; Gasperini C; Scandellari C; Totaro R; De Rossi N; Masera S; Zipoli V; Patti F;
    Neurol Sci; 2021 Jul; 42(7):2837-2845. PubMed ID: 33205373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumab.
    Roar M; Illes Z; Sejbaek T
    Mult Scler Relat Disord; 2016 Nov; 10():116-122. PubMed ID: 27919477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
    Planche V; Moisset X; Morello R; Dumont E; Gibelin M; Charré-Morin J; Saubusse A; Mondou A; Reuter F; Defer G; Pelletier J; Brochet B; Clavelou P
    J Neurol Sci; 2017 Nov; 382():148-154. PubMed ID: 29111011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
    Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
    Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.
    Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
    Pediatr Neurol; 2017 May; 70():56-60. PubMed ID: 28389054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
    Spelman T; Herring WL; Zhang Y; Tempest M; Pearson I; Freudensprung U; Acosta C; Dort T; Hyde R; Havrdova E; Horakova D; Trojano M; De Luca G; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Alroughani R; Pucci E; Granella F; Lechner-Scott J; Sola P; Ferraro D; Grand'Maison F; Terzi M; Rozsa C; Boz C; Hupperts R; Van Pesch V; Oreja-Guevara C; van der Walt A; Jokubaitis VG; Kalincik T; Butzkueven H;
    Pharmacoeconomics; 2022 Mar; 40(3):323-339. PubMed ID: 34921350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.
    Sundgren M; Piehl F; Wahlin Å; Brismar T
    Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
    Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
    CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.
    Gudesblatt M; Wissemann K; Zarif M; Bumstead B; Fafard L; Wilken J; Blitz K; Buhse M; Santra S; Hotermans C; Lee L
    CNS Drugs; 2018 Dec; 32(12):1173-1181. PubMed ID: 30143944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
    Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
    JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
    Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial.
    Rorsman I; Petersen C; Nilsson PC
    Acta Neurol Scand; 2018 Jan; 137(1):117-124. PubMed ID: 28901547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
    Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
    Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.